Skip to main content
Erschienen in: World Journal of Urology 12/2019

08.03.2019 | Original Article

Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer

verfasst von: Aaron Brant, Marcus Daniels, Meera R. Chappidi, Gregory A. Joice, Nikolai A. Sopko, Andres Matoso, Trinity J. Bivalacqua, Max Kates

Erschienen in: World Journal of Urology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Non-muscle-invasive bladder cancer involving the prostatic urethra is associated with pathologic upstaging and shorter survival. We investigated the survival impact of prostatic urethral involvement in non-muscle-invasive patients who are not upstaged at cystectomy.

Methods

From 2000 to 2016, 177 male patients underwent cystectomy for high-risk non-muscle-invasive bladder cancer and remained pT1, pTis, or pTa, and N0 on final pathology; 63 (35.6%) patients had prostatic urethral involvement and 114 (64.4%) did not. Prostatic involvement was non-invasive (Ta or Tis) in 56 (88.9%) patients and superficially invasive (T1) in 7 (11.1%) patients. No patient had stromal invasion. Log-rank and Cox regression analyses were used to evaluate survival.

Results

Compared to patients without prostatic urethral involvement, patients with involvement were more likely to have received intravesical therapy (84.6% vs. 64.4%, p < 0.01), have multifocal tumor (90.8% vs. 51.7%, p < 0.01), and have positive urethral margins (7.7% vs. 0%, p < 0.01) and ureteral margins (18.5% vs. 5.1%, p < 0.01). Log-rank comparison showed inferior recurrence-free, cancer-specific, and overall survival in patients with prostatic involvement (p = 0.01, p = 0.03, p < 0.01). Patients with prostatic urethral involvement were more likely to experience recurrence in the urinary tract (p < 0.01). On Cox regression, prostatic urethral involvement was an independent predictor of overall mortality (HR = 2.08, p < 0.01).

Conclusions

Prostatic urethral involvement is associated with inferior survival in patients who undergo cystectomy for non-muscle-invasive bladder cancer and remain pT1, pTis, or pTa on final pathology. Prostatic urethral involvement is thus an adverse pathologic feature independent of its association with upstaging.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30CrossRef Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30CrossRef
2.
Zurück zum Zitat Chang SS, Boorjian SA, Chou R et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol 196:1021–1029CrossRef Chang SS, Boorjian SA, Chou R et al (2016) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO Guideline. J Urol 196:1021–1029CrossRef
3.
Zurück zum Zitat Herr HW (1998) Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 16:1099–1102CrossRef Herr HW (1998) Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 16:1099–1102CrossRef
4.
Zurück zum Zitat Lightfoot AJ, Rosevear HM, Nepple KG et al (2012) Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer. Int J Urol 19:988–993CrossRef Lightfoot AJ, Rosevear HM, Nepple KG et al (2012) Role of routine transurethral biopsy and isolated upper tract cytology after intravesical treatment of high-grade non-muscle invasive bladder cancer. Int J Urol 19:988–993CrossRef
5.
Zurück zum Zitat Huguet J, Crego M, Sabate S et al (2005) Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48:53–59CrossRef Huguet J, Crego M, Sabate S et al (2005) Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48:53–59CrossRef
6.
Zurück zum Zitat Palou J, Sylvester RJ, Faba OR et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette–Guerin. Eur Urol 62:118–125CrossRef Palou J, Sylvester RJ, Faba OR et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette–Guerin. Eur Urol 62:118–125CrossRef
7.
Zurück zum Zitat Solsona E, Iborra I, Ricos JV et al (1995) The prostate involvement as prognostic factor in patients with superficial bladder tumors. J Urol 154:1710–1713 (discussion 59) CrossRef Solsona E, Iborra I, Ricos JV et al (1995) The prostate involvement as prognostic factor in patients with superficial bladder tumors. J Urol 154:1710–1713 (discussion 59) CrossRef
8.
Zurück zum Zitat Herr H, Solgani P (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296–1299CrossRef Herr H, Solgani P (2001) Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 166:1296–1299CrossRef
9.
Zurück zum Zitat Palou J, Wood D, Bochner BH et al (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: urothelial carcinoma of the prostate. Eur Urol 63:81–87CrossRef Palou J, Wood D, Bochner BH et al (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: urothelial carcinoma of the prostate. Eur Urol 63:81–87CrossRef
10.
Zurück zum Zitat Rikken CH, van Helsdingen PJ, Kazzaz BA (1987) Are biopsies from the prostatic urethra useful in patients with superficial bladder carcinoma? Br J Urol 59:145–147CrossRef Rikken CH, van Helsdingen PJ, Kazzaz BA (1987) Are biopsies from the prostatic urethra useful in patients with superficial bladder carcinoma? Br J Urol 59:145–147CrossRef
11.
Zurück zum Zitat von Rundstedt FC, Lerner SP, Godoy G et al (2015) Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy. J Urol 193:58–63CrossRef von Rundstedt FC, Lerner SP, Godoy G et al (2015) Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy. J Urol 193:58–63CrossRef
12.
Zurück zum Zitat Liedberg F, Anderson H, Blackberg M et al (2007) Prospective study of transitional cell carcinoma in the prostatic urethra and prostate in the cystoprostatectomy specimen Incidence, characteristics and preoperative detection. Scand J Urol Nephrol 41:290–296CrossRef Liedberg F, Anderson H, Blackberg M et al (2007) Prospective study of transitional cell carcinoma in the prostatic urethra and prostate in the cystoprostatectomy specimen Incidence, characteristics and preoperative detection. Scand J Urol Nephrol 41:290–296CrossRef
13.
Zurück zum Zitat Kates M, Ball MW, Chappidi MR et al (2016) Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urol Oncol 34:532.e1–532.e6CrossRef Kates M, Ball MW, Chappidi MR et al (2016) Accuracy of urethral frozen section during radical cystectomy for bladder cancer. Urol Oncol 34:532.e1–532.e6CrossRef
Metadaten
Titel
Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer
verfasst von
Aaron Brant
Marcus Daniels
Meera R. Chappidi
Gregory A. Joice
Nikolai A. Sopko
Andres Matoso
Trinity J. Bivalacqua
Max Kates
Publikationsdatum
08.03.2019
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 12/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02673-2

Weitere Artikel der Ausgabe 12/2019

World Journal of Urology 12/2019 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.